- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Aspirin reduces risk of colorectal cancer incidence, mortality
Aspirin taken for several years and at doses ?75 mg a day was found to result in both a reduced 20-year risk of colorectal cancer incidence and mortality, according to an analysis published ahead-of-print on the Lancet website.
Key Points
Aspirin taken for several years and at doses ≥75 mg a day was found to result in both a reduced 20-year risk of colorectal cancer incidence and mortality, according to an analysis published ahead-of-print on the Lancet website.
The authors of this study lead by Peter M. Rothwell, MD, Department of Clinical Neurology, University of Oxford, Oxford, UK, emphasized, "Benefit was greatest for cancers of the proximal colon, which are not otherwise prevented effectively by screening with sigmoidoscopy or colonoscopy."
They conducted an independent patient data meta-analysis that followed 14,033 patients for about 20 years of follow-up as part of 5 pooled randomized trials assessing the effect of aspirin on colorectal cancer incidence and mortality. Their analysis focused, not only on overall incidence and mortality rates, but also on the effect of the site of tumor and aspirin dose and duration of treatment.
The authors stressed, "The 5 trials we studied all predated endoscopic screening for adenomas, which also reduces colorectal cancer incidence and mortality, and might therefore reduce the absolute benefit of aspirin."
They also found the benefit of aspirin increased with longer durations of treatment, with participants receiving aspirin for at least 5 years exhibiting a reduced risk of proximal colon incidence and related mortality and also a reduced risk of rectal cancer incidence and mortality. Doses of aspirin ≥75 mg/d showed no additional benefit, but doses of 30 mg/d appeared less effective.
"This . . . could incite clinicians to turn to primary prevention of colorectal cancer by aspirin, at least in high-risk populations," said Robert Benamouzig, MD, and Bernard Uzzan, MD, the Departments of Gastroenterology and Pharmacology at Avicenne Hospital, France.
SOURCES
Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of 5 randomised trials. Lancet. 2010;Oct 21. [Epub ahead of print]. Available at: http://www.lancet.com/journals/lancet/article/PIIS0140-6736%2810%2961543-7/fulltext. Accessed November 20, 2010.
Benamouzig R, Uzzan B. Aspirin to prevent colorectal cancer: time to act? Lancet. 2010;Oct 21. [Epub ahead of print]. Available at: http://www.lancet.com/journals/lancet/article/PIIS0140-6736%2810%2961509-7/fulltext. Accessed November 20, 2010.
U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2006 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010. Available at: http://www.cdc.gov/uscs/. Accessed November 20, 2010.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
